Stockscreener 앱 받기
19.58
2.10%
-0.42
시간 외 거래:
19.70
0.12
+0.61%
전일 마감가:
$20.00
열려 있는:
$20
하루 거래량:
1.02M
Relative Volume:
0.68
시가총액:
$117.13M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.7389
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+14.97%
1개월 성능:
+25.19%
6개월 성능:
+37.98%
1년 성능:
-96.67%
1일 변동 폭
$19.52
$21.99
1주일 범위
$16.68
$21.99
52주 변동 폭
$7.31
$672.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
19.58 | 117.13M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -
Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks
Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Groundbreaking Cancer Therapy Shows Promise: Tonix's New Combination Treatment Activates Cancer-Killing Cells - Stock Titan
Tonix Pharmaceuticals and Makana partner to advance research with Anti-Rejection therapy - Proactive Investors
Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -
Tonix reports promising results for mpox vaccine TNX-801 By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Promising Results for Single-Dose Mpox Vaccine | TNXP Stock News - GuruFocus
Tonix reports promising results for mpox vaccine TNX-801 - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine T - GuruFocus
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - The Manila Times
Tonix Pharmaceuticals Presented Data on Potential Mpox - GlobeNewswire
Tonix Pharma Presents Promising Vaccine Data at Congress - TipRanks
Single-Dose Mpox Vaccine Breakthrough: Complete Protection for Immunocompromised Patients in Latest Trial - Stock Titan
Tonix Pharmaceuticals (TNXP) Falls Despite Market Upturn - GuruFocus
Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congres - GuruFocus
When the Price of (TNXP) Talks, People Listen - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com
Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire
Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan
Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN
Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India
Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus
Tonix and Makana partner on xenotransplantation research - Investing.com
Tonix Pharmaceuticals and Makana Therapeutics Announce - GlobeNewswire
Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix'S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana'S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies - marketscreener.com
Revolutionary Xenotransplantation Breakthrough: Tonix and Makana Join Forces to Combat Organ Failure - Stock Titan
Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management - Proactive financial news
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewswire
Game-Changing Fibromyalgia Treatment Achieves Phase 3 Success, FDA Decision Looms - Stock Titan
(TNXP) Investment Analysis - news.stocktradersdaily.com
Peering Into Tonix Pharmaceuticals's Recent Short Interest - Benzinga
TNXP: No AdCom Required for TNX-102 SL NDA… - Yahoo Finance
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharmaceuticals Reveals 5 Major Catalysts: FDA Decision, DoD Contract, and Breakthrough Therapies - Stock Titan
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com South Africa
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition - GlobeNewswire
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Lat - PharmiWeb.com
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):